Patents by Inventor Anne Marie Jeanne Bouillot
Anne Marie Jeanne Bouillot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220298125Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: June 2, 2022Publication date: September 22, 2022Inventors: Anne Marie Jeanne BOUILLOT, Olivier MIRGUET, John LIDDLE, Anne Louise WALKER
-
Patent number: 11352334Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: GrantFiled: July 24, 2019Date of Patent: June 7, 2022Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: Anne Marie Jeanne Bouillot, Olivier Mirguet, John Liddle, Anne Louise Walker
-
Patent number: 10611756Abstract: The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): or pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.Type: GrantFiled: February 8, 2019Date of Patent: April 7, 2020Assignee: The University Court of The University of EdinburghInventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Olivier Mirguet, Ann Louise Walker
-
Publication number: 20190345117Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: July 24, 2019Publication date: November 14, 2019Inventors: Anne Marie Jeanne BOUILLOT, Olivier MIRGUET, John LIDDLE, Anne Louise WALKER
-
Patent number: 10472350Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.Type: GrantFiled: March 5, 2018Date of Patent: November 12, 2019Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Nerina Dodic, Anne Marie Jeanne Bouillot
-
Publication number: 20190169178Abstract: The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): or pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.Type: ApplicationFiled: February 8, 2019Publication date: June 6, 2019Inventors: Anne Marie Jeanne BOUILLOT, Alexis DENIS, John LIDDLE, Olivier MIRGUET, Ann Louise WALKER
-
Patent number: 10273232Abstract: The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: GrantFiled: February 20, 2018Date of Patent: April 30, 2019Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Ann Louise Walker
-
Publication number: 20190100517Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: December 3, 2018Publication date: April 4, 2019Inventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Ann Louise Walker
-
Patent number: 10246447Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: GrantFiled: May 19, 2016Date of Patent: April 2, 2019Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Anne Marie Jeanne Bouillot, Alexis Denis, John Liddle, Olivier Mirguet, Ann Louise Walker
-
Publication number: 20180194756Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.Type: ApplicationFiled: March 5, 2018Publication date: July 12, 2018Inventors: Nerina DODIC, Anne Marie Jeanne BOUILLOT
-
Publication number: 20180170920Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: May 19, 2016Publication date: June 21, 2018Inventors: Anne Marie Jeanne BOUILLOT, Alexis DENIS, John LIDDLE, Olivier MIRGUET, Ann Louise WALKER
-
Publication number: 20180170921Abstract: The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: February 20, 2018Publication date: June 21, 2018Inventors: Anne Marie Jeanne BOUILLOT, Alexis Denis, John Liddle, Ann Louise Walker
-
Publication number: 20180127405Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =0; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: May 19, 2016Publication date: May 10, 2018Inventors: Anne Marie Jeanne BOUILLOT, Alexis DENIS, John LIDDLE, Ann Louise WALKER
-
Patent number: 9938260Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.Type: GrantFiled: September 18, 2015Date of Patent: April 10, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Nerina Dodic, Anne Marie Jeanne Bouillot
-
Patent number: 9932328Abstract: Compound of formula (I) wherein: R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: GrantFiled: December 17, 2015Date of Patent: April 3, 2018Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Anne Marie Jeanne Bouillot, Alexis Denis, Ann Louise Walker, John Liddle
-
Publication number: 20170349577Abstract: Compound of formula (I) wherein: R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ?O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: December 17, 2015Publication date: December 7, 2017Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Anne Marie Jeanne BOUILLOT, Alexis DENIS, Ann Louise WALKER, John LIDDLE
-
Publication number: 20170305888Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.Type: ApplicationFiled: September 18, 2015Publication date: October 26, 2017Inventors: Nerina DODIC, Anne Marie Jeanne BOUILLOT
-
Publication number: 20160318884Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.Type: ApplicationFiled: December 17, 2014Publication date: November 3, 2016Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Anne Marie Jeanne BOUILLOT, Olivier MIRGUET, John LIDDLE, Anne Louise WALKER
-
Patent number: 9051281Abstract: The present invention relates to substituted triazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.Type: GrantFiled: June 21, 2013Date of Patent: June 9, 2015Assignee: GlaxoSmithKline LLCInventors: Anne Marie Jeanne Bouillot, Alain Laroze, Lionel Trottet
-
Publication number: 20130345243Abstract: The present invention relates to pyrimidinedione compounds of formula (I), salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds of formula (I) or salts thereof as activators of AMPK.Type: ApplicationFiled: March 5, 2012Publication date: December 26, 2013Applicant: GLAXOSMITHKLINE LLCInventors: Anne Marie Jeanne Bouillot, Alain Claude-Marie Daugan, Yann Lamotte, Olivier Mirguet